{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T21:42:35Z","timestamp":1776462155587,"version":"3.51.2"},"reference-count":71,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.jval.2013.07.004","type":"journal-article","created":{"date-parts":[[2013,9,16]],"date-time":"2013-09-16T08:40:20Z","timestamp":1379320820000},"page":"1081-1090","source":"Crossref","is-referenced-by-count":22,"title":["Complete Cytogenetic Response and Major Molecular Response as Surrogate Outcomes for Overall Survival in First-Line Treatment of Chronic Myelogenous Leukemia: A Case Study for Technology Appraisal on the Basis of Surrogate Outcomes Evidence"],"prefix":"10.1016","volume":"16","author":[{"given":"Ciani","family":"Oriana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoyle","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavey","family":"Toby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cooper","family":"Chris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garside","family":"Ruth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudin","family":"Claudius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Rod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2013.07.004_bib1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"issue":"Suppl. 5","key":"10.1016\/j.jval.2013.07.004_bib2","doi-asserted-by":"crossref","first-page":"v165","DOI":"10.1093\/annonc\/mdq201","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Baccarani","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jval.2013.07.004_bib3","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jval.2013.07.004_bib4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1200\/JCO.2009.26.5587","article-title":"Chronic myeloid leukemia: reversing the chronic phase","volume":"28","author":"Goldman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2013.07.004_bib5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/JBM.S13067","article-title":"First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation","volume":"3","author":"Piccaluga","year":"2012","journal-title":"J Blood Med"},{"key":"10.1016\/j.jval.2013.07.004_bib6","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2013.07.004_bib7","unstructured":"Haematological Malignancy Research Network. Chronic myelogenous leukaemia. Available from: http:\/\/www.hmrn.org\/Statistics\/Cancer_Info.aspx?id=1. [Accessed July 23, 2012]."},{"key":"10.1016\/j.jval.2013.07.004_bib8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1470-2045(09)70028-2","article-title":"Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England","volume":"10","author":"Rachet","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2013.07.004_bib9","unstructured":"Cancer, Research, UK. Leukaemia incidence statistics. 2011. Available from: http:\/\/www.cancerresearchuk.org\/cancer-info\/cancerstats\/types\/leukaemia\/incidence\/uk-leukaemia-incidence-statistics#Prevalence. [Accessed February 26, 2013]."},{"key":"10.1016\/j.jval.2013.07.004_bib10","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.jval.2013.07.004_bib11","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2013.07.004_bib12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jval.2013.07.004_bib13","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jval.2013.07.004_bib14","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2013.07.004_bib15","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2013.07.004_bib16","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jval.2013.07.004_bib17","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jval.2013.07.004_bib18","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2013.07.004_bib19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug","volume":"1","author":"Capdeville","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jval.2013.07.004_bib20","unstructured":"National Institute for Health and Care Excellence. Leukaemia (Chronic Myeloid)\u2014Imatinib (TA70). 2003. Available from: http:\/\/www.nice.org.uk\/ta70. [Accessed July 23, 2012]."},{"key":"10.1016\/j.jval.2013.07.004_bib21","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2013.07.004_bib22","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2013.07.004_bib23","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","article-title":"Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jval.2013.07.004_bib24","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jval.2013.07.004_bib25","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood-2012-03-378919","article-title":"How I treat newly diagnosed chronic phase CML","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jval.2013.07.004_bib26","unstructured":"National Institute for Health and Care Excellence. NICE recommends nilotinib and standard dose imatinib for first line chronic myeloid leukaemia. 2012. Available from: http:\/\/www.nice.org.uk\/newsroom\/pressreleases\/NilotinibAndImatinibForCMLDraftGuidance.jsp. [Accessed July 23, 2012]."},{"key":"10.1016\/j.jval.2013.07.004_bib27","first-page":"7","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jval.2013.07.004_bib28","unstructured":"National Institute for Health and Care Excellence. Leukaemia (chronic myeloid, first line)\u2014dasatinib, nilotinib and standard-dose imatinib: final appraisal determination. 2012. Available from: http:\/\/guidance.nice.org.uk\/TA\/Wave24\/15\/FAD. [Accessed July 23, 2012]."},{"key":"10.1016\/j.jval.2013.07.004_bib29","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"iii","key":"10.1016\/j.jval.2013.07.004_bib30","first-page":"1","article-title":"Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis","volume":"8","author":"Dalziel","year":"2004","journal-title":"Health Technol Assess (Winchester, England)"},{"key":"10.1016\/j.jval.2013.07.004_bib31","unstructured":"Centre for Reviews and Dissemination. Undertaking Systematic Reviews of Research on Effectiveness: CRD\u2019s Guidance for Carrying Out or Commissioning Reviews (2nd ed.). CRD Report 4. York: NHS Centre for Reviews and Dissemination, 2001."},{"key":"10.1016\/j.jval.2013.07.004_bib32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1017\/S0266462309090023","article-title":"Use of surrogate outcomes in cost-effectiveness models: a review of United Kingdom health technology assessment reports","volume":"25","author":"Elston","year":"2009","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.jval.2013.07.004_bib33","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1200\/JCO.2008.16.1000","article-title":"Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables","volume":"26","author":"Anderson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2013.07.004_bib34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/01621459.1927.10502953","article-title":"Probable inference, the law of succession, and statistical inference","volume":"22","author":"Wilson","year":"1927","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jval.2013.07.004_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1198\/016214505000001302","article-title":"Assessing evidence inconsistency in mixed treatment comparisons","volume":"101","author":"Lu","year":"2006","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jval.2013.07.004_bib36","series-title":"WinBUGS User Manual: Version 1.4","author":"Spiegelhalter","year":"2003"},{"key":"10.1016\/j.jval.2013.07.004_bib37","series-title":"Methods for Meta-Analysis in Medical Research","author":"Sutton","year":"2000"},{"issue":"iii\u2013iv","key":"10.1016\/j.jval.2013.07.004_bib38","first-page":"1","article-title":"Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses","volume":"16","author":"Pavey","year":"2012","journal-title":"Health Technol Assess (Winchester, England)"},{"key":"10.1016\/j.jval.2013.07.004_bib39","unstructured":"GAD. Life tables. Available from: http:\/\/www.gad.gov.uk\/Demography%20Data\/Life%20Tables\/. [Accessed March 13, 2011]."},{"key":"10.1016\/j.jval.2013.07.004_bib40","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2013.07.004_bib41","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jval.2013.07.004_bib42","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jval.2013.07.004_bib43","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jval.2013.07.004_bib44","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","article-title":"Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials","volume":"108","author":"Roy","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jval.2013.07.004_bib45","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","article-title":"The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jval.2013.07.004_bib46","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2013.07.004_bib47","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/cncr.23238","article-title":"Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.jval.2013.07.004_bib48","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2013.07.004_bib49","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1080\/10428190701824585","article-title":"Imatinib mesylate in early chronic phase chronic myeloid leukemia: experience from a developing country","volume":"49","author":"Rajappa","year":"2008","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.jval.2013.07.004_bib50","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.jval.2013.07.004_bib51","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jval.2013.07.004_bib52","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.1182\/blood-2011-05-352252","article-title":"Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining","volume":"119","author":"Chakraborty","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jval.2013.07.004_bib53","doi-asserted-by":"crossref","first-page":"6180","DOI":"10.1182\/blood-2012-05-423897","article-title":"BCR\/ABL and chromosomal instability: debate resolved","volume":"119","author":"Carroll","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jval.2013.07.004_bib54","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1182\/blood-2011-07-369041","article-title":"Dasatinib inhibits proinflammatory functions of mature human neutrophils","volume":"119","author":"Futosi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jval.2013.07.004_bib55","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2012-03-418582","article-title":"The shady side of dasatinib","volume":"119","author":"Zarbock","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jval.2013.07.004_bib56","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1001\/jama.282.8.771","article-title":"Users\u2019 guides to the medical literature, XIX: applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group","volume":"282","author":"Bucher","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2013.07.004_bib57","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/0962280207082719","volume":"17","author":"Lassere","year":"2008","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jval.2013.07.004_bib58","series-title":"The Evaluation of Surrogate Endpoints","author":"Burzykowski","year":"2005"},{"key":"10.1016\/j.jval.2013.07.004_bib59","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/cncr.20674","article-title":"Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia","volume":"101","author":"Anstrom","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2013.07.004_bib60","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood.V99.5.1527","article-title":"A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia","volume":"99","author":"Baccarani","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jval.2013.07.004_bib61","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jval.2013.07.004_bib62","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199707243370402","article-title":"Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group","volume":"337","author":"Guilhot","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2013.07.004_bib63","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2013.07.004_bib64","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/10428190500473055","article-title":"Development of a predictive population survival model according to the cytogenetic response rate for patients with chronic myeloid leukemia in the chronic phase","volume":"47","author":"Schrover","year":"2006","journal-title":"Leukemia Lymphoma"},{"issue":"1","key":"10.1016\/j.jval.2013.07.004_bib65","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3324\/haematol.2012.063172","article-title":"Has the time for first-line treatment with second generation tyrosinekinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis","volume":"98","author":"Gurion","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jval.2013.07.004_bib66","unstructured":"European Medicines Agency. Glivec: EPAR\u2014scientific discussion. 2005. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000406\/human_med_000808.jsp&mid=WC0b01ac058001d124. [Accessed July 23, 2012]."},{"key":"10.1016\/j.jval.2013.07.004_bib67","doi-asserted-by":"crossref","first-page":"c221","DOI":"10.1136\/bmj.c221","article-title":"Meta-analysis of individual participant data: rationale, conduct, and reporting","volume":"340","author":"Riley","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2013.07.004_bib68","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1200\/JCO.2011.39.6655","article-title":"Not only response but early response to tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2013.07.004_bib69","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1001\/jama.2009.1409","article-title":"Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada","volume":"302","author":"Clement","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2013.07.004_bib70","unstructured":"Institute for Quality and Efficiency in Healthcare. Validity of surrogate endpoints in oncology. 2011. Available from: https:\/\/www.iqwig.de\/a10-05-validity-of-surrogate-endpoints-in.986.en.html?tid=1325&random=f6799f. [Accessed July 23, 2012]."},{"key":"10.1016\/j.jval.2013.07.004_bib71","unstructured":"National Institute for Health and Care Excellence. Review of the Guide to the Methods of Technology Appraisal. 2012. Available from: http:\/\/www.nice.org.uk\/aboutnice\/howwework\/devnicetech\/TAMethodsGuideReview.jsp?domedia=1&mid=CB13DD0D-19B9-E0B5-D4AB0011AEE2B0E7. [Accessed July 23, 2012]."}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301513019025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301513019025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T03:00:54Z","timestamp":1596510054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301513019025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1098301513019025"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2013.07.004","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}